The Circulating Cell-Free Tumor DNA market is estimated to be valued at US$ 6.1 Bn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Circulating cell-free tumor DNA (ctDNA) refers to pieces of DNA that are shed by tumors into the bloodstream. ctDNA is collected through a simple blood draw and can be used to detect cancer, determine the stage and type of cancer, monitor cancer progression or recurrence, and guide personalized treatment decisions. ctDNA can be analyzed through next-generation sequencing to provide insights into genomic alterations in the tumor. This non-invasive approach has wide applications in cancer research and diagnostics.
Market Dynamics:
The circulating cell-free tumor DNA market is driven by wide applications in cancer research and diagnostics. ctDNA offers a non-invasive alternative to tissue biopsies for comprehensive cancer genomic profiling which helps in personalized treatment decisions. It also aids in monitoring tumor responses, detecting relapse, or progression. With advancements in next-generation sequencing technologies, ctDNA analysis is gaining importance in early cancer detection as well as monitoring cancer recurrence and metastasis. Furthermore, increasing prevalence of cancer worldwide is also contributing to the growth of this market.
SWOT Analysis
Strength: The circulating cell-free tumor DNA market has the potential to revolutionize cancer diagnostics and monitoring. Liquid biopsies provide minimally invasive alternatives to tissue biopsies. Technologies can detect multiple tumor mutations from a simple blood draw. Early detection leads to improved outcomes and treatment choices.
Weakness: Challenges remain in detecting extremely low levels of ctDNA in early-stage cancers. Specificity and sensitivity must improve for widespread clinical adoption. Current technologies are not applicable to all cancer types and stages. Cost of sequencing and data analysis remains high.
Opportunity: Growing need for non-invasive and repeatable cancer screening drives the market. Technologies enable earlier detection, real-time monitoring of treatment response and minimal residual disease assessment. Expanding applications to new cancer types, treatment monitoring and recurrence detection present opportunities for growth.
Threats: Stringent regulatory policies for approval delay market penetration. Reimbursement challenges restrict adoption by payors. Ethical issues around incidental findings require addressing. Emerging competitors threaten market share of established players.
Key Takeaways
The Global Circulating Cell-free Tumor DNA Market Size is expected to witness high growth, exhibiting CAGR of 22% over the forecast period, due to increasing prevalence of cancer worldwide. According to WHO, cancer burden is projected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040.
Regional analysis
North America dominates the circulating cell-free tumor DNA market currently, owing to high awareness, robust healthcare infrastructure and presence of key market players. Asia Pacific is poised to grow at the fastest pace during the forecast period due to large patient pool, rising healthcare spending and improving diagnostic technologies in countries like China and India.
Key players
Key players operating in the circulating cell-free tumor DNA market are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
Read more
https://www.rapidwebwire.com/circulating-cell-free-tumor-dna-market-size-share-growth-outlook-2023/
